[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362983-105":59,"doc-detail-362983-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","prospective-multicenter-study-of-ctdna-versus-tumor-tissue-guiding-fgfr-targeted-therapy-in-metastatic-urothelial-cancer-received","Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer - Received","","Prospective multicentre evidence evaluates whether plasma circulating tumor DNA (ctDNA) can complement tissue-based testing for fibroblast growth factor receptor (FGFR) alterations to guide targeted therapy in metastatic urothelial cancer. In patients undergoing clinical FGFR tissue testing for erdaﬁtinib eligibility, ctDNA showed high concordance with tissue results and identified additional actionable FGFR alterations. Baseline ctDNA had 84% sensitivity for tissue-detected alterations and revealed seven extra cases; serial sampling further clarified FGFR status. In treated patients, median progression-free survival was 7.5 months, supporting clinical uptake of ctDNA testing alongside tissue approaches.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prospective-multicenter-study-of-ctdna-versus-tumor-tissue-guiding-fgfr-targeted-therapy-in-metastatic-urothelial-cancer-received/362983/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prospective-multicenter-study-of-ctdna-versus-tumor-tissue-guiding-fgfr-targeted-therapy-in-metastatic-urothelial-cancer-received/362983.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in metastatic urothelial cancer?","Question",{"text":112,"@type":113},"FGFR alterations are actionable but are currently identified mainly through tissue testing, which can be limited by sample availability, heterogeneity, and assay variability. The study assesses whether ctDNA can add value alongside tissue-based approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How well did ctDNA testing agree with tissue FGFR testing?",{"text":117,"@type":113},"Among 125 patients with paired baseline ctDNA and tissue results, FGFR status was concordant in 90%. ctDNA also showed 84% sensitivity for alterations detected in tissue.",{"name":119,"@type":110,"acceptedAnswer":120},"Did ctDNA identify FGFR alterations not found in tissue?",{"text":121,"@type":113},"Yes. ctDNA identified seven additional cases with FGFR alterations that were not captured by tissue testing in the paired analysis. Serial plasma collections were also used to clarify FGFR status over time.",{"name":123,"@type":110,"acceptedAnswer":124},"What treatment outcomes were observed after using ctDNA/tissue-guided testing?",{"text":125,"@type":113},"In 21 patients who received erdaﬁtinib after testing, the median progression-free survival was 7.5 months. One patient with a ctDNA-exclusive FGFR alteration remained on erdaﬁtinib for 33 months.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},362983,1790784990,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article [https://doi.org/10.1038/s41467-026-69927-7](https://doi.org/10.1038/s41467-026-69927-7)  \nProspective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer  \nReceived: 9 October 2025  \n\n| Accepted: 9 February 2026 |\n| --- |\n| |\n| Check for updates |\n\nA list of authors and their afﬁliations appears at the end of the paper  \nFibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity. Plasma circulating tumor DNA (ctDNA) offers a complementary testing strategy, but the added value of ctDNA relative to conventional FGFR alteration assessment remains unclear. Here, in a prospective, multicentre study, we show that ctDNA testing has high concordance with tissue FGFR testing and identiﬁes additional actionable FGFR alterations. We proﬁle plasma from208patients with mUC undergoing clinical FGFR tissue testing for erdaﬁtinib eligibility. In evaluable baseline samples, FGFR alteration frequency is26%in either tissue or ctDNA. Among 125 patients with baseline detected ctDNA and paired tissue results, FGFR status is concordant in 90%, and ctDNA has an 84% sensitivity for tissuedetected alterations while also identifying 7 additional cases. Serial plasma collections post-baseline further clarify FGFR status. In 21 patients who received erdaﬁtinib after testing, the median progression-free survival is 7.5 months, and one patient with a ctDNA-exclusive FGFR alteration remained on erdaﬁtinib for 33 months. Our results support clinical uptake of ctDNA FGFR testing in combination with tissue-based approaches in mUC.  \nActivating alterations in the ﬁbroblast growth factor receptor (FGFR) genes are oncogenic drivers in several cancers, including urothelial cancer where FGFR3 alterations are present in 20-60% of patients depending on stage and presentation1–4. FGFR3 alterations introduce a therapeutic vulnerability, and the pan-FGFR small-molecule inhibitor erdaﬁtinib is an approved treatment option in metastatic urothelial cancer (mUC)5. Second-generation agents with improved FGFR3 speciﬁcity and reduced toxicity are in clinical development for mUC, and there are ongoing efforts to test FGFR inhibition earlier in disease6,7. However, a barrier to effective implementation of FGFR inhibition in mUC is the need for accurate and timely identiﬁcation of FGFR3 alterations.  \nConstitutive FGFR3 activation in mUC commonly arises through hotspot mutations in the ligand-binding or transmembrane domains, or through gene fusions involving the intracellular domain8. In the United States, the approved companion diagnostic for erdaﬁtinib is a  \nqualitative RT-PCR tumor tissue test that detects nine recurrent FGFR alterations (4 hotspot mutations and 5 fusions)5. Outside the US, local diagnostic labs use a variety of tests, often amplicon-based due to cost, speed, and reliability. However, no internationally standardized testing approach exists, contributing to assay-dependent variability in patientselection and access to FGFR-targeted therapies. Reliance on singlefoci, archival tissue samples for testing is a further limitation given the well-documented intra-patient heterogeneity of FGFR3 alteration status, and a tissue test failure rate of 14-34% depending on the population9–12.  \nTo address these challenges, we designed a pan-Canadian prospective study (NCT06129084) to evaluate the potential added value of plasma-derived circulating tumor DNA (ctDNA) testing to standard tissue-based approaches for FGFR gene alteration detection in mUC. Plasma ctDNA offers a minimally-invasive, real-time snapshot of the dominant tumor population, particularly at the time of clinical disease  \ne-mail: [gvandekerkhove@prostatecentre.com](gvandekerkhove@prostatecentre.com); [alexander.wyatt@ubc.ca](alexander.wyatt@ubc.ca); bernie.eigl@bcca","cbCaiaRdxek0XS1b","https://ap.wps.com/l/cbCaiaRdxek0XS1b","pdf",928456,"English","# Prospective multicenter study overview\n## FGFR alterations and the testing challenge\n## ctDNA as a complementary strategy\n# Study design and cohort\n## Screening and enrollment\n## Inclusion and testing workflow\n# Results\n## Concordance between ctDNA and tissue\n## Sensitivity and additional actionable alterations\n## Serial plasma collections and treatment outcomes\n# Implications for clinical practice","[{\"question\":\"What problem does the study address in metastatic urothelial cancer?\",\"answer\":\"FGFR alterations are actionable but are currently identified mainly through tissue testing, which can be limited by sample availability, heterogeneity, and assay variability. The study assesses whether ctDNA can add value alongside tissue-based approaches.\"},{\"question\":\"How well did ctDNA testing agree with tissue FGFR testing?\",\"answer\":\"Among 125 patients with paired baseline ctDNA and tissue results, FGFR status was concordant in 90%. ctDNA also showed 84% sensitivity for alterations detected in tissue.\"},{\"question\":\"Did ctDNA identify FGFR alterations not found in tissue?\",\"answer\":\"Yes. ctDNA identified seven additional cases with FGFR alterations that were not captured by tissue testing in the paired analysis. Serial plasma collections were also used to clarify FGFR status over time.\"},{\"question\":\"What treatment outcomes were observed after using ctDNA/tissue-guided testing?\",\"answer\":\"In 21 patients who received erdaﬁtinib after testing, the median progression-free survival was 7.5 months. One patient with a ctDNA-exclusive FGFR alteration remained on erdaﬁtinib for 33 months.\"}]","Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer - Received | PDF",1790149587,25,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e6ab2abd6e569abcaa9f72e56fdccf6.webp",983,1305,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b98fb933a783059d822673669e8173bc.webp",982,1304,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a4f6ed9c248fd740616ea7450e7664b.webp",981,1303,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54d2cf5a9dde70bf086eaa7689c252c9.webp",980,1301]